Press Releases

11.21.2016

Pfizer Announces Expiration And Results Of Tender Offer For Any And All Of Its 6.200% Senior Notes Due March 15, 2019

11.18.2016

Pfizer Announces Pricing of Tender Offer for Any and All of its 6.200% Senior Notes Due March 15, 2019

11.16.2016

PALOMA-2 Phase 3 Study Published In The New England Journal Of Medicine Demonstrates Clinical Benefit Of Pfizer’s IBRANCE® (palbociclib) In First-Line ER+, HER2- Metastatic Breast Cancer

11.15.2016

Pfizer Announces Results from Phase 3 OPAL Clinical Development Program Investigating XELJANZ® (Tofacitinib Citrate) for Psoriatic Arthritis

11.14.2016

Pfizer Prices $6,000,000,000 Debt Offering

11.14.2016

Pfizer Announces Tender Offer for Any and All of its 6.200% Senior Notes Due March 15, 2019

11.14.2016

Pfizer to Collaborate with National Cancer Institute to Study Three Immunotherapy Agents Targeting Multiple Cancers

11.13.2016

Landmark Study Demonstrates Pfizer’s Celebrex (Celecoxib)Has Similar Cardiovascular Risk As Compared To Prescription Doses Of Ibuprofen and Naproxen

11.11.2016

Pfizer Announces Major Expansion of Humanitarian Assistance Program

11.10.2016

Bristol-Myers Squibb and Pfizer to Deliver 12 New Eliquis® (apixaban) Presentations at American Heart Association (AHA) Scientific Sessions 2016

11.09.2016

IBRANCE® (palbociclib) Receives Approval in European Union for the Treatment of Women with HR+/HER2- Metastatic Breast Cancer

11.07.2016

Pfizer to Present Additional Research For XELJANZ® (Tofacitinib Citrate) In Rheumatologic Diseases, Including Rheumatoid Arthritis and Psoriatic Arthritis